Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 4/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | CYBB | P04839 | 1/20 | 0.38 |
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3322494 | 0.83 | HTR1D (0.53) | HTR1BHTR6CYBBNCF1ALDH1A1 | |
| SCHEMBL3320947 | 0.78 | NUDT1 (0.35) | MAOA | |
| SCHEMBL14024446 | 0.77 | PDE3B (0.37) | MAOACYBBNCF1 | |
| SCHEMBL3320715 | 0.76 | PDE3B (0.34) | MAOACYBBNCF1 | |
| SCHEMBL3317233 | 0.75 | MEN1 (0.50) | HTR1BSMN1; SMN2LTA4H | |
| SCHEMBL3320336 | 0.74 | MEN1 (0.52) | HTR7HTR1BADRB2LTA4H | |
| SCHEMBL3321913 | 0.74 | MEN1 (0.49) | SMN1; SMN2LTA4H | |
| SCHEMBL7535239 | 0.73 | HTR7 (0.77) | HTR7HTR1BHTR6CHRNB2CHRNA4 | |
| SCHEMBL3321404 | 0.73 | MEN1 (0.45) | KDM4EALDH1A1 | |
| SCHEMBL3322480 | 0.72 | HRH3 (0.55) | NCF1TDO2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258301-B2 | Urotensin II receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-04 | — | — | US | claimed |
| US-8258301-B2 | Urotensin II receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| US-8258301-B2 | Urotensin II receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| US-20100121051-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-13 | — | — | US | disclosed |
| US-20100121051-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121051-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, AGTR1, AGTR2 | HTR7 386/4885MAOA 2249/4885HTR1B 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.